- Home
- SYRS vs CNSP Comparison
SYRS vs CNSP Comparison
Compare SYRS & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRS
- CNSP
- Stock Information
- Founded
- SYRS 2011
- CNSP 2017
- Country
- SYRS United States
- CNSP United States
- Employees
- SYRS N/A
- CNSP N/A
- Industry
- SYRS Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- SYRS Health Care
- CNSP Health Care
- Exchange
- SYRS Nasdaq
- CNSP Nasdaq
- Market Cap
- SYRS 5.7M
- CNSP 6.5M
- IPO Year
- SYRS 2016
- CNSP 2019
- Fundamental
- Price
- SYRS $0.17
- CNSP $3.23
- Analyst Decision
- SYRS Hold
- CNSP Strong Buy
- Analyst Count
- SYRS 5
- CNSP 1
- Target Price
- SYRS $3.00
- CNSP $0.50
- AVG Volume (30 Days)
- SYRS 1.2M
- CNSP 941.1K
- Earning Date
- SYRS 03-26-2025
- CNSP 03-31-2025
- Dividend Yield
- SYRS N/A
- CNSP N/A
- EPS Growth
- SYRS N/A
- CNSP N/A
- EPS
- SYRS N/A
- CNSP N/A
- Revenue
- SYRS $386,000.00
- CNSP N/A
- Revenue This Year
- SYRS N/A
- CNSP N/A
- Revenue Next Year
- SYRS N/A
- CNSP N/A
- P/E Ratio
- SYRS N/A
- CNSP N/A
- Revenue Growth
- SYRS N/A
- CNSP N/A
- 52 Week Low
- SYRS $0.16
- CNSP $2.81
- 52 Week High
- SYRS $7.96
- CNSP $1,195.00
- Technical
- Relative Strength Index (RSI)
- SYRS 38.78
- CNSP 35.22
- Support Level
- SYRS $0.16
- CNSP $4.60
- Resistance Level
- SYRS $0.20
- CNSP $9.50
- Average True Range (ATR)
- SYRS 0.02
- CNSP 0.94
- MACD
- SYRS 0.01
- CNSP -0.15
- Stochastic Oscillator
- SYRS 35.75
- CNSP 6.28
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.